Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2005
05/19/2005WO2003049678A3 Mitotic kinesin inhibitors
05/19/2005WO2003009815A3 Compositions and methods for modulating blood-brain barrier transport
05/19/2005US20050107616 Alpha-ketoamide derivatives as cathepsin k inhibitors
05/19/2005US20050107606 Process for producing optically active sulfoxide derivative
05/19/2005US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles
05/19/2005US20050107460 N-heteroaryl-, naphthyl or azulenyl-substituted 1-azabicycloalkylcarboxamides; treatment and/or prophylaxis of impairments of perception, concentration, learning and/or memory
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107449 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X
05/19/2005US20050107446 Two components mixture comprising a powder of atorvastatin with an alkalizing agent that forms a pH greater than 5 and a second component without the alkalizing agent; treating angina pectoris, hypertension, atherosclerosis
05/19/2005US20050107445 Active compounds with carbamic acid for diseases such as cancer, leukemia, atheriosclerosis, alzheimers disease or arthritis
05/19/2005US20050107435 antibiotics such as (5S,5S')-N-(3-{4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,2'-difluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide, used for treating a bacterial infections in mammals
05/19/2005US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders
05/19/2005US20050107429 Aqueous liquid preparations and light-stabilized aqueous liquid preparations
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107421 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases
05/19/2005US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases
05/19/2005US20050107411 Method for treating circadian rhythm disruptions
05/19/2005US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
05/19/2005US20050107404 Mitotic kinesin inhibitors
05/19/2005US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions
05/19/2005US20050107397 Sulfonamide derivatives as d3-receptor agonists
05/19/2005US20050107393 4-(diarylmethyl)-1-piperazinyl derivatives
05/19/2005US20050107390 i.e. 7-[(3R)-3-Amino-4-(3,4-difluorophenyl)butanoyl]-3-methyl-6-(phenylmethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, dihydrochloride; antilipemic, antiobesity
05/19/2005US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC
05/19/2005US20050107380 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle
05/19/2005US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders
05/19/2005US20050107375 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
05/19/2005US20050107367 2-(morpholin-4-yl)-6-phenyl-thiopyran-4-one; treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK
05/19/2005US20050107356 synergistic effect; CB1 receptor antagonist is an azetidine compound of given formula such as 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine), and the dopaminergic agent is ropinirole for example
05/19/2005US20050107354 Preventive or therapeutic agent for kidney disease
05/19/2005US20050107347 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
05/19/2005US20050107340 Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease
05/19/2005US20050107330 Drug mixture contains a sympathomimetic selected from the group consisting oxymetazoline, xylometazoline, tramazoline, tetryzoline and naphazoline, and glycosaminoglycan of hyaluronic acid; synergistic effect; vasoconstrictor action, detumescent action on the nose mucous membrane
05/19/2005US20050107309 Lowering elevated post-prandial blood glucose levels by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity; insulinotropic effects are enhanced
05/19/2005US20050107291 Compositions and methods for treating or preventing diseases of body passageways
05/19/2005US20050107256 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
05/19/2005US20050106724 Self renewing dental follicle tissues for use in generating periodontal ligament like membrane structures; tissue repair and regenerative medicine
05/19/2005US20050106695 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
05/19/2005US20050106679 Leptin proteins
05/19/2005US20050106678 Human circulating cytokine CC-1
05/19/2005US20050106675 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/19/2005US20050106674 Ephrin receptor binding protein for use as tool in treatment and prevention of cell proliferative and nervous system disorders
05/19/2005US20050106670 Isolated human G-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human GPCR proteins, and uses thereof
05/19/2005US20050106658 Remodeling and glycoconjugation of peptides
05/19/2005US20050106638 Immunoglobulin for use in diagnosis, prevention and treatment of fibrosis and scarring; antiscarring agents
05/19/2005US20050106568 Method of quantifying nucleic acid and kit for quantifying nucleic acid
05/19/2005US20050106237 Orodispersible pharmaceutical composition comprising perindopril
05/19/2005US20050106236 5-Ht4partial agonist pharmaceutical compositions
05/19/2005US20050106231 Liposome-entrapped topoisomerase inhibitors
05/19/2005US20050106220 Administering gamma-aminobutyric acid receptor antagonist
05/19/2005US20050106217 Adjust fatty acid oxidation; stimulating carnitine palmitoyl transferase
05/19/2005US20050106215 Food or pet food composition containing plant extract for bone health
05/19/2005US20050106212 Using electrochemical mixture of metal compound and bioactive material; contacting substrate
05/19/2005US20050106191 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
05/19/2005US20050106186 Percutaneous preparations
05/19/2005US20050106140 Antagonistic anti-hfas ligand human antibodies and fragments thereof
05/19/2005US20050106136 Controlling capilalries, blood vessels in eye; vision defects
05/19/2005US20050106133 Containing lactobacillus; storage stability
05/19/2005US20050106131 Photoprotective orally administrable composition for skin
05/19/2005US20050106127 Graft to humans; culture product; removing cells; preservation
05/19/2005CA2545157A1 Disinfecting composition and methods of making and using same
05/19/2005CA2543199A1 Use of crth2 antagonist compounds in therapy
05/18/2005EP1531153A1 Epothilone derivatives
05/18/2005EP1530724A2 Diagnosis and prevention of cancer cell invasion
05/18/2005EP1530638A2 T-cell epitopes in staphylococcal enterotoxin b
05/18/2005EP1530573A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors
05/18/2005EP1530568A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE
05/18/2005EP1530567A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
05/18/2005EP1530565A1 Substituted thiophene carboxamide compounds for the treatment of inflammation
05/18/2005EP1530476A1 Use of reboxetine for the treatment of hot flashes
05/18/2005EP1530474A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors
05/18/2005EP1430030B1 N-type calcium channel antagonists for the treatment of pain
05/18/2005EP1341909B1 A method for in vitro molecular evolution of protein function
05/18/2005EP1317430B1 (2-azabicyclo [2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
05/18/2005EP1301184B1 Valproic acid and derivatives thereof as histone deacetylase inhibitors
05/18/2005EP1265860B1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
05/18/2005EP1263724B1 Novel compounds
05/18/2005EP1263421B1 The dual inhibitor of cholesteryl ester and wax ester synthesis avasimibe for treating sebaceous gland disorders
05/18/2005EP1261367B1 Use of interleukin-6 antagonists for the treatment of oestrogen dependent tumours
05/18/2005EP1233787B8 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
05/18/2005EP1224195B1 C-aryl glucoside sglt2 inhibitors
05/18/2005EP1207156B1 Substituted benzylthiazolidine-2,4-dione derivatives
05/18/2005EP1098885B9 Imidazole compounds and their use as adenosine deaminase inhibitors
05/18/2005EP0946173B1 Preparation of 3-fluoro oxindole derivatives
05/18/2005EP0830138B1 Use of fibroblast growth factor analogues to stimulate bone growth
05/18/2005EP0820461B1 Aryl-ester phosphoramidate derivatives of 2',3'-didehydronucleosides
05/18/2005CN1617928A Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
05/18/2005CN1617887A Corticotropin releasing factor receptor 2 agonists
05/18/2005CN1617886A Corticotropin releasing factor receptor 2 agonists
05/18/2005CN1617885A Corticotropin releasing factor receptor 2 agonists
05/18/2005CN1617874A Hexacyclic compounds
05/18/2005CN1617871A Purine derivatives as purinergic receptor antagonists
05/18/2005CN1617870A N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
05/18/2005CN1617865A Phenylalkynes
05/18/2005CN1617862A Novel 1, 2, 4-thiadiazole derivatives as melanocortin receptor modulators
05/18/2005CN1617859A 5-sulfanyl-4h-1, 2, 4-triazole derivatives and their use as a medicament
05/18/2005CN1617858A Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1)
05/18/2005CN1617856A Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
05/18/2005CN1617855A Inhibitors of cytosolic phospholipase A2
05/18/2005CN1617852A Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
1 ... 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 ... 1564